Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas

• Thrombosis-free survival as assessed by objectively documented deep vein thrombosis or pulmonary embolism [ Time Frame: until dvt or death ] [ Designated as safety issue: Yes ]
  

• ABO blood group association with venous thromboembolism (VTE) factor VIII activity and VTE as assessed by laboratory test result at study entry [ Time Frame: on study ] [ Designated as safety issue: No ]
  

OBJECTIVES:

Primary

• Determine the overall hazard rate of first venous thromboembolism per person-year of follow-up in patients undergoing antineoplastic therapy for newly diagnosed high-grade gliomas.
• Correlate ABO blood type with incidence of venous thromboembolism in these patients.
• Correlate factor VIII level with incidence of venous thromboembolism in these patients.

Secondary

• Determine the overall and individual incidence rate of thromboembolism in these patients.
• Correlate clinical variables, such as type of antineoplastic treatments, Karnofsky performance status, and type of tumor, with incidence of venous thromboembolism in these patients.
• Correlate demographic factors, such as age, with incidence of venous thromboembolism in these patients.

OUTLINE: This is a pilot, multicenter study.

Patients undergo blood collection for blood typing (if not already obtained) and factor VIII and C-reactive protein levels at baseline. Patients are followed to obtain information on their Karnofsky performance status, treatment they receive for their brain tumor, and occurrence of any thrombotic events (e.g., pulmonary embolism or deep-vein thrombosis). Patients are followed every 28 days until the development of thrombotic events, after which they are followed every 2 months for survival.

PROJECTED ACCRUAL: A total of 107 patients will be accrued for this study.